Fig. 6: Epithelial polarization after CD5/βLNP-FAPCAR 2.2 therapy. | Nature Communications

Fig. 6: Epithelial polarization after CD5/βLNP-FAPCAR 2.2 therapy.

From: Targeted immunotherapy rescues pulmonary fibrosis by reducing activated fibroblasts and regulating alveolar cell profile

Fig. 6

A Western blot images and quantification of EMT marker genes and Cdc42 protein expressions (n = 4). B Proteomic heatmap for macrophage markers. C Flow cytometry analysis for percentages of macrophage (marked by F4/80) in lung cells (n = 4). D Flow cytometry plot for a comparison of M1/M2 phenotypes between BLM+Saline and CD5/βLNP groups. CD86: marker for M1 phenotype; CD163: marker for M2 phenotype. E Representative immunofluorescence images of macrophages in lung tissue. (Cyan: F4/80; Red: iNOS; Green: CD163; White: DAPI) (Scar bar:20 μm). F, G Representative immunofluorescence images showing the position of polarization factors, Cdc42 and Pkcz(aPKC) in cells (Red: Cdc42; Green: Pkcz; White: DAPI) (Scar bar: 10 μm and 5 μm). H Representative immunofluorescence images of key molecules in regulating epithelial polarization. (Blue: DAPI; Red: Calponin; Green: Pkcz zeta; White: Cldn 5) (Scale bar: 20 μm and 10 μm). I Relative abundance of proteins relevant to angiogenesis (Vegfa, Eng) and carbon dioxide regulation (Ca4, Ca13) (n = 4). ‘n’ means independent biological replications. The values are the means ± SDs. *P < 0.05. P-value determined by one-way ANOVA followed by Tukey’s multiple comparisons test (A, C) and two-tailed unpaired Student’s t-test (I). (EMT: epithelial-mesenchymal transformation). Source data are provided as a Source Data file.

Back to article page